Bhavin Makwana

Ahead of the conference, we launched a delegate survey to gather insights on what participants hoped to gain from the three-day event, as well as the key challenges currently facing pharma contract manufacturing. The survey explored critical topics such as supply chain disruptions, the impact of geopolitical tensions, and the ongoing debate between localisation and centralisation.

In this session, our Advisory Board will review the survey findings, address delegates’ most pressing concerns, and facilitate an open discussion on the issues that matter most to those in the room. 

Natural disasters, conflicts, labour shortages, and other recent global disruptions have illustrated how fragile pharmaceutical supply chains can be. As a result, risk mitigation strategies are essential and having a secondary supplier in place for the manufacturing of life-saving medicines should no longer be a nice to have but an essential part of outsourcing strategy.

In this session, our expert panellists will explore dual sourcing and splitting molecule production, focusing on four key dimensions: risk management, regulatory compliance, operational execution, and business strategy. They will share practical insights on how pharma companies and CMOs can implement dual sourcing effectively without compromising compliance, cost, or speed-to-market.

Key benefits of dual sourcing to be discussed include:

• Increased capacity and flexibility: Ensuring manufacturing scalability to meet fluctuating global demand.
• Enhanced supply chain resilience: Mitigating the impact of regional disruptions, quality issues, or supplier shutdowns.
• Improved supplier negotiation and leverage: Fostering competitive pricing, service quality, and stronger partnerships.